Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferons as antiangiogenic agents.

Daniel J Lindner1

  • 1Taussig Cancer Center, The Cleveland Clinic Foundation, R40, 9500 Euclid Avenue, Cleveland, OH 44195, USA. lindned@cc.ccf.org

Current Oncology Reports
|October 2, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia.

Molecular cancer·2026
Same author

AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia.

Research square·2026
Same author

METTL16 promotes taxane resistance in Triple-Negative Breast Cancer through m <sup>6</sup> A-dependent translational upregulation of ABCB1.

bioRxiv : the preprint server for biology·2026
Same author

The CDK inhibitor Roscovitine enhances the therapeutic efficacy of anti-PD-1 in non-small cell lung cancer.

Frontiers in oncology·2026
Same author

Synergistic effect of MDM2 inhibitors and radiotherapy in endometrial cancer.

NPJ precision oncology·2025
Same author

The effects of dietary fat on gut microbial composition and function in a mouse model of ovarian cancer.

Journal of ovarian research·2025
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Interferons (IFNs) are the first identified natural inhibitors of blood vessel growth. They reduce tumor cell secretion of growth factors, and their antiangiogenic effects are boosted by combining them with other agents.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Interferons (IFNs) are key regulators of immune responses, including antiviral and antitumor activities.
  • IFNs were the first identified endogenous regulators of angiogenesis.
  • Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.

Purpose of the Study:

  • To review the role of interferons (IFNs) as endogenous antiangiogenic regulators.
  • To highlight the mechanisms by which IFNs inhibit angiogenesis.
  • To discuss the potential of combining IFNs with other antiangiogenic agents.

Main Methods:

  • Review of existing literature on interferons and angiogenesis.
  • Analysis of studies investigating IFN-mediated inhibition of angiogenic factors.

Related Experiment Videos

  • Examination of combination therapies involving IFNs and other antiangiogenic agents.

    • Main Results:

    • IFNs exhibit species-specific inhibition of angiogenic factor secretion, such as basic fibroblast growth factor (bFGF), from tumor cells.
    • The antiangiogenic activity of IFNs is significantly enhanced when used in combination with agents like tamoxifen and thalidomide.
    • IFNs represent a critical class of endogenous molecules with direct antiangiogenic properties.

    Conclusions:

    • Interferons are potent endogenous antiangiogenic factors with therapeutic potential in cancer.
    • Combination strategies involving IFNs and other antiangiogenic agents may offer enhanced efficacy in cancer treatment.
    • Further research into IFN-based therapies could lead to novel approaches for controlling tumor growth by inhibiting angiogenesis.